|
Gene: PRKCB |
Gene summary for PRKCB |
Gene summary. |
Gene information | Species | Human | Gene symbol | PRKCB | Gene ID | 5579 |
Gene name | protein kinase C beta | |
Gene Alias | PKC-beta | |
Cytomap | 16p12.2-p12.1 | |
Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | P05771 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5579 | PRKCB | EOLP-1 | Human | Oral cavity | EOLP | 1.20e-22 | 7.29e-01 | -0.0202 |
5579 | PRKCB | EOLP-2 | Human | Oral cavity | EOLP | 5.10e-13 | 5.17e-01 | -0.0203 |
5579 | PRKCB | NEOLP-3 | Human | Oral cavity | NEOLP | 1.37e-02 | 1.88e-01 | -0.0191 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | EOLP: Erosive Oral lichen planus | |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001810514 | Oral cavity | EOLP | peptidyl-serine phosphorylation | 84/2218 | 315/18723 | 3.32e-13 | 1.05e-10 | 84 |
GO:001820914 | Oral cavity | EOLP | peptidyl-serine modification | 87/2218 | 338/18723 | 1.07e-12 | 2.46e-10 | 87 |
GO:000276413 | Oral cavity | EOLP | immune response-regulating signaling pathway | 108/2218 | 468/18723 | 4.04e-12 | 7.34e-10 | 108 |
GO:190165323 | Oral cavity | EOLP | cellular response to peptide | 85/2218 | 359/18723 | 2.06e-10 | 2.06e-08 | 85 |
GO:001657023 | Oral cavity | EOLP | histone modification | 98/2218 | 463/18723 | 5.58e-09 | 2.96e-07 | 98 |
GO:002241121 | Oral cavity | EOLP | cellular component disassembly | 94/2218 | 443/18723 | 1.00e-08 | 4.89e-07 | 94 |
GO:004343424 | Oral cavity | EOLP | response to peptide hormone | 89/2218 | 414/18723 | 1.29e-08 | 6.11e-07 | 89 |
GO:003286922 | Oral cavity | EOLP | cellular response to insulin stimulus | 53/2218 | 203/18723 | 1.65e-08 | 7.43e-07 | 53 |
GO:007137523 | Oral cavity | EOLP | cellular response to peptide hormone stimulus | 68/2218 | 290/18723 | 1.98e-08 | 8.62e-07 | 68 |
GO:003286823 | Oral cavity | EOLP | response to insulin | 62/2218 | 264/18723 | 7.78e-08 | 2.76e-06 | 62 |
GO:004312223 | Oral cavity | EOLP | regulation of I-kappaB kinase/NF-kappaB signaling | 58/2218 | 249/18723 | 2.72e-07 | 8.22e-06 | 58 |
GO:001821015 | Oral cavity | EOLP | peptidyl-threonine modification | 35/2218 | 125/18723 | 7.33e-07 | 1.85e-05 | 35 |
GO:000724924 | Oral cavity | EOLP | I-kappaB kinase/NF-kappaB signaling | 62/2218 | 281/18723 | 8.00e-07 | 2.02e-05 | 62 |
GO:001810715 | Oral cavity | EOLP | peptidyl-threonine phosphorylation | 33/2218 | 116/18723 | 1.02e-06 | 2.51e-05 | 33 |
GO:00027683 | Oral cavity | EOLP | immune response-regulating cell surface receptor signaling pathway | 66/2218 | 315/18723 | 2.44e-06 | 5.45e-05 | 66 |
GO:000828615 | Oral cavity | EOLP | insulin receptor signaling pathway | 32/2218 | 116/18723 | 3.06e-06 | 6.70e-05 | 32 |
GO:00510811 | Oral cavity | EOLP | nuclear envelope disassembly | 8/2218 | 11/18723 | 4.54e-06 | 9.41e-05 | 8 |
GO:00024292 | Oral cavity | EOLP | immune response-activating cell surface receptor signaling pathway | 60/2218 | 291/18723 | 1.16e-05 | 2.00e-04 | 60 |
GO:00027572 | Oral cavity | EOLP | immune response-activating signal transduction | 60/2218 | 291/18723 | 1.16e-05 | 2.00e-04 | 60 |
GO:00303971 | Oral cavity | EOLP | membrane disassembly | 8/2218 | 12/18723 | 1.22e-05 | 2.09e-04 | 8 |
Page: 1 2 3 4 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517146 | Oral cavity | EOLP | Coronavirus disease - COVID-19 | 108/1218 | 232/8465 | 8.08e-33 | 2.61e-30 | 1.54e-30 | 108 |
hsa0516442 | Oral cavity | EOLP | Influenza A | 58/1218 | 171/8465 | 7.01e-11 | 3.23e-09 | 1.91e-09 | 58 |
hsa0541545 | Oral cavity | EOLP | Diabetic cardiomyopathy | 64/1218 | 203/8465 | 2.48e-10 | 1.00e-08 | 5.91e-09 | 64 |
hsa0516345 | Oral cavity | EOLP | Human cytomegalovirus infection | 68/1218 | 225/8465 | 5.29e-10 | 1.90e-08 | 1.12e-08 | 68 |
hsa0407141 | Oral cavity | EOLP | Sphingolipid signaling pathway | 44/1218 | 121/8465 | 1.19e-09 | 3.51e-08 | 2.07e-08 | 44 |
hsa0517043 | Oral cavity | EOLP | Human immunodeficiency virus 1 infection | 63/1218 | 212/8465 | 4.85e-09 | 8.71e-08 | 5.14e-08 | 63 |
hsa0451026 | Oral cavity | EOLP | Focal adhesion | 60/1218 | 203/8465 | 1.42e-08 | 1.83e-07 | 1.08e-07 | 60 |
hsa0502245 | Oral cavity | EOLP | Pathways of neurodegeneration - multiple diseases | 110/1218 | 476/8465 | 1.09e-07 | 1.26e-06 | 7.40e-07 | 110 |
hsa0516141 | Oral cavity | EOLP | Hepatitis B | 49/1218 | 162/8465 | 1.38e-07 | 1.54e-06 | 9.07e-07 | 49 |
hsa04670210 | Oral cavity | EOLP | Leukocyte transendothelial migration | 37/1218 | 114/8465 | 7.00e-07 | 6.85e-06 | 4.04e-06 | 37 |
hsa046622 | Oral cavity | EOLP | B cell receptor signaling pathway | 29/1218 | 84/8465 | 2.75e-06 | 2.11e-05 | 1.25e-05 | 29 |
hsa0466623 | Oral cavity | EOLP | Fc gamma R-mediated phagocytosis | 31/1218 | 97/8465 | 7.90e-06 | 4.73e-05 | 2.79e-05 | 31 |
hsa0520543 | Oral cavity | EOLP | Proteoglycans in cancer | 53/1218 | 205/8465 | 9.07e-06 | 5.33e-05 | 3.14e-05 | 53 |
hsa04650 | Oral cavity | EOLP | Natural killer cell mediated cytotoxicity | 38/1218 | 132/8465 | 1.26e-05 | 7.01e-05 | 4.13e-05 | 38 |
hsa0406643 | Oral cavity | EOLP | HIF-1 signaling pathway | 33/1218 | 109/8465 | 1.48e-05 | 8.08e-05 | 4.76e-05 | 33 |
hsa0401223 | Oral cavity | EOLP | ErbB signaling pathway | 27/1218 | 85/8465 | 3.39e-05 | 1.69e-04 | 9.94e-05 | 27 |
hsa040642 | Oral cavity | EOLP | NF-kappa B signaling pathway | 31/1218 | 104/8465 | 3.72e-05 | 1.82e-04 | 1.07e-04 | 31 |
hsa0152124 | Oral cavity | EOLP | EGFR tyrosine kinase inhibitor resistance | 25/1218 | 79/8465 | 7.03e-05 | 3.25e-04 | 1.91e-04 | 25 |
hsa0401023 | Oral cavity | EOLP | MAPK signaling pathway | 68/1218 | 302/8465 | 7.48e-05 | 3.40e-04 | 2.01e-04 | 68 |
hsa0521424 | Oral cavity | EOLP | Glioma | 24/1218 | 75/8465 | 8.01e-05 | 3.59e-04 | 2.12e-04 | 24 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRKCB | SNV | Missense_Mutation | c.1690N>G | p.Met564Val | p.M564V | P05771 | protein_coding | deleterious(0) | possibly_damaging(0.466) | TCGA-50-5930-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | taxotere | PD | |
PRKCB | SNV | Missense_Mutation | c.1741N>T | p.Gly581Cys | p.G581C | P05771 | protein_coding | deleterious(0.01) | possibly_damaging(0.563) | TCGA-55-5899-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | CR | |
PRKCB | SNV | Missense_Mutation | novel | c.1293N>A | p.His431Gln | p.H431Q | P05771 | protein_coding | tolerated(0.93) | benign(0.097) | TCGA-55-8089-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PRKCB | SNV | Missense_Mutation | c.1279N>C | p.Asp427His | p.D427H | P05771 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-55-8207-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
PRKCB | SNV | Missense_Mutation | novel | c.1133N>A | p.Val378Glu | p.V378E | P05771 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-55-8506-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCB | SNV | Missense_Mutation | c.473N>T | p.Arg158Leu | p.R158L | P05771 | protein_coding | tolerated(0.07) | benign(0.367) | TCGA-55-8507-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
PRKCB | SNV | Missense_Mutation | c.189N>T | p.Gln63His | p.Q63H | P05771 | protein_coding | deleterious(0.02) | possibly_damaging(0.702) | TCGA-67-3771-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PRKCB | SNV | Missense_Mutation | c.1991N>T | p.Ser664Phe | p.S664F | P05771 | protein_coding | deleterious(0) | benign(0.124) | TCGA-86-8278-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | etoposide | SD | |
PRKCB | SNV | Missense_Mutation | c.1555N>A | p.Gly519Arg | p.G519R | P05771 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-86-8672-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
PRKCB | SNV | Missense_Mutation | novel | c.217N>T | p.Val73Leu | p.V73L | P05771 | protein_coding | deleterious(0.03) | possibly_damaging(0.841) | TCGA-86-8673-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | BRYOSTATIN | BRYOSTATIN | ||
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | inhibitor | 178102647 | ||
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | atenolol | ATENOLOL | ||
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | Sotrastaurin acetate | |||
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | BISINDOLYLMALEIMIDE IX | BISINDOLYLMALEIMIDE IX | 25058929 | |
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | inhibitor | 249565629 | SOTRASTAURIN | |
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | dexmedetomidine | DEXMEDETOMIDINE | ||
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | INGENOL MEBUTATE | |||
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | inhibitor | 178101880 | ||
5579 | PRKCB | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSPORTER | inhibitor | CHEMBL494089 | GSK-690693 |
Page: 1 2 3 4 |